Home › Myasthenia Gravis › Ohio
Myasthenia Gravis clinical trials in Ohio
12 studies for Myasthenia Gravis are looking for participants at sites in Ohio.
Cities in Ohio
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1038, Cincinnati
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Nov 13, 2026 · NCT07039916A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0039 10103, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07465289A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10102, Cincinnati
- Mg0038 10103, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07463521A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT04951622A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Cleveland
- TG Therapeutics Investigational Trial Site, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06680037ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- University of Cincinnati Medical Center - Goodman St, Cincinnati
- Ohio State Martha Morehouse Outpatient Care, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07294170Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
- The Ohio State University Wexner Medical Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06626919Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Miami Valley Hospital South, Centerville
- University of Cincinnati, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06463587ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- University of Cincinnati Medical Center - Goodman St, Cincinnati
- Ohio State Martha Morehouse Outpatient Care, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420Zilucoplan for Severe gMG Exacerbations
- The Ohio State University, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07215949Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- The Ohio State University, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06414954Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Dayton
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT04202341From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.